FDA approves IV maintenance dosing of Leqembi® (lecanemab-irmb) for the treatment of early Alzheimer's Disease in the US
BioArctic AB (publ) (NASDAQ STOCKHOLM: BIOA B) today announced that the U.S. Food and Drug Administration (FDA) has approved ...
BioArctic: FDA approves IV maintenance dosing of Leqembi (lecanemab-irmb) for the treatment of early Alzheimer's Disease in the US
BioArctic AB (publ) (NASDAQ STOCKHOLM: BIOA B) today announced that the U.S. Food and Drug Administration (FDA) has approved BioArctic's partner Eisai's ...
Thailand Business News2h
Thailand’s pharmaceutical industry: a cornerstone of the nation’s economy and healthcare infrastructure
Thailand’s pharmaceutical industry has emerged as a key sector in the nation’s economic and healthcare landscape, reflecting robust growth and strategic ...
H2O Radio8h
Why Leaving the Paris Agreement May Not Be a Bad Thing
As he did during his first term, Trump announced that he is pulling the U.S. out of the Paris Agreement on climate that aims ...